Geron shares surged 6.72% driven by updated financial guidance and strategic initiatives.

Geron’s shares surged 6.7164% in pre-market trading on January 13, 2026, driven by updated financial guidance and strategic initiatives. The biopharmaceutical company outlined 2026 expectations for RYTELO (imetelstat), forecasting net product revenue between $220 million and $240 million, alongside total operating expenses in a similar range. The guidance highlights a focus on streamlining operations and reducing costs year-over-year, reflecting recent restructuring efforts. Management emphasized a targeted commercial strategy to boost RYTELO’s market penetration in the U.S. and expand into international lower-risk myelodysplastic syndromes (LR-MDS) markets.

Key developments include an amended loan facility extending Tranche B and C funding options to July 2026, providing financial flexibility. The company also expanded its clinical evidence for RYTELO through new data from the Phase 3 IMerge trial, reinforcing its position as a differentiated treatment. Leadership cited stronger second-half revenue growth potential due to focused physician and patient engagement, while cost reductions from restructuring are expected to support long-term sustainability.

These moves align with Geron’s broader goal to establish itself as a leading hematology company through RYTELO’s commercial and therapeutic advancements. With a clear roadmap of operational efficiency, financial prudence, and clinical differentiation, the company aims to deliver long-term value for shareholders while advancing its therapeutic offerings across global markets.